

## Special Issue

# Antimicrobial Resistance and Healthcare Associated Infections

### Message from the Guest Editors

Antimicrobial resistance (AMR) is a global health and development threat that requires urgent multisector action in order to achieve goals and to implement effective prevention measures. Healthcare-associated infections (HCAI) due to microorganisms that are antimicrobial resistant are today one of the most important challenges in modern medicine. One major preventive goal is preventing infections and maintaining optimal antimicrobial treatment, so that we could consequently prevent all avoidable HCAI but especially make sure that non-avoidable infections are at the very least treatable. Misuse and overuse of antimicrobials are the main drivers in the development of multidrug-resistant pathogens. In the same manner, inadequate infection prevention and control promotes the spread of these microorganisms. In addition, the costs of AMR to the economy are significant, and the same is true for death, disability, prolonged illness resulting in longer hospital stays, and the need for more expensive medicines and financial challenges that have a negative impact both at an individual and social level.

### Guest Editors

Prof. Dr. Thaís Guimarães

1. Infection Control Department, Instituto Central, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil
2. Infection Control Department, Hospital do Servidor Público Estadual de São Paulo, São Paulo 04039-000, Brazil

Prof. Dr. Silvia Figueiredo Costa

1. Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 470, São Paulo 05403-000, Brazil
2. Department of Infectious Diseases, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil

### Deadline for manuscript submissions

closed (31 December 2022)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/108551](https://mdpi.com/si/108551)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)